Navigation Links
Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
Date:4/30/2009

of capital converted, and the consolidation of its common shares on a 10 for 1 basis. The transfer of the assets of the Neurobionix division will also be implemented by way of the plan of arrangement.

Victhom expects to hold separate debenture holder and shareholder meetings in early June to obtain certain required approvals for the above-mentioned plan of arrangement as well as the creation of the JV. Further details on the plan of arrangement and the transaction with Otto Bock will be provided in an information management circular expected to be distributed to its shareholders and debenture holders by mid-May. In addition to debenture holders and shareholders approvals, implementation of the JV transaction and the plan of arrangement is subject to approval by the Court under the Canada Business Corporations Act and receipt of all necessary regulatory and stock exchange approvals.

The principal debenture holders and shareholders have executed support agreements with Victhom and Otto Bock whereby they agreed to vote in favor of the transaction with Otto Bock and the concurrent implementation of the plan of arrangement.

The board of directors of Victhom is recommending to both the shareholders and the debenture holders to support the transaction as it will provide Victhom with the opportunity to develop its technologies under new parameters providing a stronger financial base for the future.

Mr. Normand Rivard, Acting President and CFO of Victhom, said: "We are tremendously enthusiastic with the prospect of teaming up with Otto Bock, the world leader in the field of mobility. This partnership is designed to exploit the great potential of our unique Neurobionix technology platform incorporated in the Neurostep. The combination of our technology know-how and Otto Bock's worldwide market knowledge will give us a tremendous edge in bringing this much needed solution to gait patients throughout the world. The interest from Otto Bock is a v
'/>"/>

SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)
2. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
3. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
4. Victhom announces the completion of the second phase of the apnea therapy development
5. Victhom Announces Launch of Enhanced Company Website
6. Victhom to Participate in the OneMedPlace Finance Forum
7. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
8. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.
9. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
10. E&K Scientific Announces Partnership with Sciformatix
11. PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
(Date:12/13/2014)... Taiwan (PRWEB) December 12, 2014 Trend ... indicators in overall global economic growth, Eugene Arthurs, CEO ... photonics , said in a featured talk at OPTIC ... December at the National Chung Hsing University in Taichung. ... being integrated into future energy supplies and soon to ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3
... July 9 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced it has obtained new ... of the ATS Open,Pivot(R) Mechanical Heart Valve., ... Open Pivot valve was implanted in Lausanne, Switzerland,on ...
... Wash., July 9 CellCyte Genetics,Corporation (CellCyte) (OTC ... to provide strategic investment and financial advice and,services. ... its two,core platform technologies and will work with ... development and commercialization of,CellCyte,s cell expander and stem ...
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today proudly ... General Manager of WuXi AppTec,s Atlanta Operations, one ... Inc., has been invited,to join the Association for ...
Cached Biology Technology:ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 2WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... could save thousands of lives a year, University of Utah ... disorder leading to unpredictable, sometimes fatal, hemorrhagic strokes, seizures, paralysis ... that millions of people take to control high cholesterol. ... in a pilot trial with people, statins could provide a ...
... Two international teams of researchers have made significant gains ... skin condition that can be debilitating in some patients. ... two studies published this week in the advance online ... studies help us get closer to realizing the promise ...
... (NIH) has awarded three contracts for pilot projects ... to medium-sized clinical studies. Each of the two-year ... $4 million, represents a collaboration among individuals at ... and Translational Science Awards (CTSA). Administered by the ...
Cached Biology News:Statins may treat blood vessel disorder that can lead to fatal strokes 2Statins may treat blood vessel disorder that can lead to fatal strokes 3Scientists uncover new genetic variations linked to psoriasis 2Scientists uncover new genetic variations linked to psoriasis 33 new informatics pilot projects to aid clinical and translational scientists nationwide 2
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Image Analysis Software. PC Version of NIH Image....
Biology Products: